OBJECTIVE: There has been no clear evidence supporting similar chemo-responses for upper and lower @entity189 . METHODS: We conducted a multicenter retrospective cohort study to analyze @entity189 @entity1 who underwent systemic chemotherapy at 17 centers from 2004 to 2010. A total of 298 @entity1 with either @entity150 (N = 151) or upper tract @entity189 (N = 147) were included. Differences in @entity5 location ( @entity150 vs. upper tract @entity189 ) were evaluated in relation to the @entity1 backgrounds and clinical responses to systemic chemotherapy. RESULTS: Overall 216 @entity1 were treated with @entity900 -based chemo-regimens ( @entity136 and @entity900 in 92, or @entity1499 , @entity5713 , @entity632 and @entity900 / @entity1499 , @entity1259 and @entity900 in 124). Among 186 initially metastatic @entity1 , the incidences of lung @entity3 and liver @entity3 were 39.2 and 34.1%, respectively, in upper tract @entity189 @entity1 , and were significantly higher than those with @entity150 (22.4% for lung; 8.4% for liver @entity3 ). Among 112 post-surgical recurrent/metastatic @entity1 , age was significantly higher and estimated glomerular filtration rate at baseline was significantly lower in upper tract @entity189 @entity1 than those with @entity150 . No significant differences were observed in overall clinical response rates for systemic chemotherapy between @entity150 (45.8%) and upper tract @entity189 (38%) in initially metastatic @entity1 or between @entity150 (43.2%) and upper tract @entity189 (44.1%) in post-surgical recurrent/metastatic @entity1 . @entity5 location was not independently associated with @entity5 -specific survival in either initially metastatic or post-surgical recurrent/metastatic @entity189 @entity1 . CONCLUSIONS: No significant difference was observed in response rates of @entity150 and upper tract @entity189 to systemic chemotherapy, suggesting that a similar chemo-regimen can be applied to metastatic @entity189 @entity1 regardless of @entity5 location (upper vs. lower).

Do metastatic upper tract @entity189 and XXXX have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma', 'urothelial carcinomas'] @entity150 :: ('MESH:D001749', 'Disease') :: ['urothelial carcinoma of the bladder'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity150 :: (MESH:D001749,Disease) :: ['bladder carcinoma']
